Swift Biosciences, Inc. today announced the launch of an early access program for Accel-NGS™ Amplicon Panels for use with Illumina Next Generati on Sequencing (NGS) systems. The assays are compatible with FFPE and circulating cell free DNA from 10 ng of genomic DNA. The underlying technology enables hundreds of primer pa irs to be amplified in a single tube. The panels can be used to target either contiguous cove rage of a single gene, multiple loci throughout the genome, or a combination of both.
The initial product is a comprehensive TP53 panel, a clinically important tumor suppressor gene.* This panel covers all coding exons of TP53 in a sin gle tube format. Another panel under development based on this technology targets over 2 00 clinically relevant oncology mutations. Swift Biosciences will also soon offer custom panel design capability.
“We are excited about offering an early access prog ram for translational...
Accel-NGS Amplicon Panels for Illumina add to the g rowing portfolio of products from Swift Biosciences. This new family of products joins the Accel-NGS 1S DNA and Accel-NGS 2S DNA Library Prep kits launched earlier in 2014.
About Swift Biosciences
Swift Biosciences is developing innovative and enab ling technologies for genomics research. The company’s Accel-NGS products bring unique capabilit ies to improve the efficiency and quality of (NGS) sample preparation. Accel-NGS library prepar ation kits offer superior sequence coverage metrics, even from challenging samples. The company has also developed qPCR reagents for mu tation detection. The myT® Primer technology provides both high sensitivity and speci ficity in somatic mutation detection, making it ideal for cancer research and diagnostic applica tions. To date, Swift has developed myT Primer assays for common mutations in the BRAF and KRAS ge nes that offer best in class sensitivity.